HKU and NICE signed an MoU intended to strengthen Hong Kong–Yangtze River Delta collaboration on innovation, applied research, commercialization, and talent development. The agreement, announced June 2, 2026, sets a strategic framework aimed at accelerating technology transfer and scaling industrial tech innovation through coordinated projects. While not a single drug program, the collaboration is a platform-level catalyst for biotech-adjacent applied R&D ecosystems in the region and can influence how industrial partners translate lab discoveries into commercial offerings.